Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
10
×
biotech
boston blog main
10
×
life sciences
national blog main
10
×
boston top stories
clinical trials
national top stories
san francisco blog main
national
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
allergan
cancer
europe blog main
europe top stories
novartis
astrazeneca
eli lilly
glaxosmithkline
alzheimer's disease
amgen
What
bio
roundup
abbvie’s
acquisitions
biotech
blood
cancer
ceo
daniel
day
days
debut
drug
fda
gilead
ipo
labor
life
medicine
medicines
moves
opioid
o’day
science
sciences
treatment
week
won
abbvie
advance
ahead
alkermes
alliance
anemia
announced
antipsychotic
august
barbecuing
benefits
biggest
Language
unset
10
×
Current search:
abbvie
×
unset
×
" national blog main "
×
" boston blog main "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More